DPP4 and COVID-19: However, gliptins do not bind to the suggested binding site of SARS-CoV-2, meaning that the wealth of data surrounding DPP4 may serve a basis for the development of new drugs, as opposed to a direct repurposing of DPP4i for treatment of COVID-19 [4].